GSK’s (GSK) Buy Rating Reiterated at Shore Capital Group

Shore Capital Group restated their buy rating on shares of GSK (LON:GSK) in a research report report published on Wednesday morning, Marketbeat.com reports. The firm currently has a GBX 2,300 target price on the stock.

GSK has been the topic of a number of other reports. Berenberg Bank increased their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Citigroup reissued a “buy” rating and set a GBX 1,900 target price on shares of GSK in a research note on Tuesday, January 27th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. Finally, UBS Group restated a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a research note on Friday, January 23rd. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of GBX 1,867.86.

GSK Stock Up 4.8%

GSK stock opened at GBX 2,180 on Wednesday. The business’s 50-day moving average price is GBX 1,846.14 and its 200 day moving average price is GBX 1,666.64. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The firm has a market cap of £87.96 billion, a price-to-earnings ratio of 16.39, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,066.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, sell-side analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insider Activity

In related news, insider Jonathan Symonds purchased 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The shares were purchased at an average cost of GBX 2,114 per share, with a total value of £52,850. Also, insider Wendy Becker acquired 441 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was purchased at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. In the last 90 days, insiders have purchased 4,591 shares of company stock valued at $9,069,269. Insiders own 0.20% of the company’s stock.

GSK News Roundup

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK Chair Sir Jonathan Symonds purchased 2,500 shares at GBX 2,114 (≈£52,850), signaling insider confidence. GSK Chair Sir Jonathan Symonds Buys Additional Shares in the Company
• Positive Sentiment: EU approved GSK’s Nucala for use in uncontrolled COPD — expands label and addressable market for an existing respiratory franchise. EU gives GSK’s Nucala green light for use in uncontrolled COPD
• Positive Sentiment: EU granted adult approval for GSK’s RSV vaccine — a major commercial milestone that supports revenue growth expectations for respiratory vaccines. GSK RSV Vaccine Wins EU Adult Approval As Shares Trade Above Targets
• Positive Sentiment: Brokerage action: Shore Capital reaffirmed a “buy” rating and GBX 2,300 target — provides independent support for upside vs. current levels. Broker Ratings
• Positive Sentiment: Q4 results beat: GSK reported stronger-than-expected Q4 profit and highlighted strategic execution — this underpins near-term earnings momentum. GSK PLC Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Market commentary/valuation pieces note a ~47% one-year share gain and debate whether the stock remains attractively valued — useful context for investors weighing further upside vs. valuation risk. Is GSK Still Attractive After A 47% One-Year Share Price Gain
• Negative Sentiment: Guidance caution: Management flagged a likely slowdown in sales growth for 2026 under the new CEO — raises near-term growth concerns and tempers the upbeat reaction to approvals and the quarter. GSK sees slower sales growth in 2026

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.